Mark Turner is Professor of Neonatology and Research Delivery at the University of Liverpool, UK. He graduated from Manchester University with a medical degree in 1991 and a PhD in 1999 (placental physiology). He trained in neonatal medicine in the North West of England and has worked as a Consultant Neonatologist in Liverpool since 2005.
His research aims to improve the access of newborn babies and children to high quality medicines. This has included studies of dosing, safety, and efficacy of 15 medicines (contributing to writing 5 paediatric investigation plans); excipient kinetics; manipulations of medicines; the assessment of adverse drug reactions; and the value of age-appropriate formulations.
He believes that the coherent integration of the design and conduct of clinical trials is key to improving the quality of medicines. He works to develop efficient medicines research infrastructure in Europe and globally as Chair of the European Network for Paediatric Research at the European Medicines Agency (EnprEMA) (2013 – 2019), Convenor of the European Paediatric Clinical Trials Research Infrastructure, co-Director of the International Neonatal Consortium and as co-Coordinator of the Collaborative Network for European Clinical Trials For Children (conect4children, c4c).